Health Care/Hospital

Nuevocor presents pre-clinical data at ESGCT and AHA meetings

SINGAPORE, Nov. 7, 2023 /PRNewswire/ -- Nuevocor, a pre-clinical stage biotechnologycompany focused on developing cardiac genetic medicines through a unique platform to understand the mechanobiological causes of disease, announced today a pair of presentations at two major meetings, the European ...

2023-11-07 22:00 1447

Recruitment target achieved for Phase II SAR-Bombesin prostate cancer trial

SYDNEY, Nov. 7, 2023 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce that 50 patients have no...

2023-11-07 21:58 1067

Turn Biotechnologies First to Deliver mRNA into the Dermis Using Proprietary LNPs, With No Distribution to Other Organs

* Company's eTurna™ delivery platform ensures unprecedented precision, safety * In-vivo biodistribution of mRNA into dermal cells, tissues shows high transfection efficiency, gene expression * Data presented at ASDS Annual Meeting MOUNTAIN VIEW, Calif., Nov. 7, 2023 /PRNewswire/ -- Turn Biot...

2023-11-07 21:30 2295

Kexing Biopharm Attended CPHI Worldwide 2023

SHENZHEN, China, Nov. 7, 2023 /PRNewswire/ -- Recently, CPHI Worldwide 2023 was successfully held inBarcelona, Spain. Kexing Biopharm exhibited more than ten kinds of high-quality medical products in the fields of tumor, autoimmune, anti-virus, etc., including Infliximab, Adalimumab, Bevacizumab,...

2023-11-07 20:09 1219

Akeso's Cadonilimab (PD-1/CTLA-4) Phase III Trial Meets Primary Endpoint at Interim Analysis Demonstrating Strong Overall Survival Benefit as First-line Treatment in All-comer Patients with Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC)

HONG KONG, Nov. 7, 2023 /PRNewswire/ -- Akeso (9926.HK) announced positive results from an interim analysis of AK104-302 study, a randomized, double-blind, multicenter, phase III clinical study evaluating PD-1/CTLA-4 bispecific antibody, cadonilimab (开坦尼®) in combination with capecitabine plus...

2023-11-07 20:00 1704

Registration for the 7th IFPA Conference 2024 now open

STOCKHOLM, Nov. 7, 2023 /PRNewswire/ -- IFPA (International Federation of Psoriasis Associations) is thrilled to announce the 7th IFPA Conference (former World Psoriasis & Psoriatic Arthritis Conference), set to take place fromJune 27 to 29, 2024, in the vibrant city of Stockholm, Sweden. Establi...

2023-11-07 18:00 1528

First Mover of Global Trade Index Based On Biome Molecule, Kwanyoung Park of AndKwan Natural Science

* Creating world-class innovation by redefining how international standards are established with eco-friendly bio materials and a system. * Patent registration for one-stop system from procurement of raw materials and golden time orders from all over the world to search for optimal routes for ...

2023-11-07 15:47 1459

Antech launches first comprehensive veterinary diagnostics offering in the UK, including a new state-of-the-art reference laboratory

Antech to offer UK veterinary professionals a complete and flexible diagnostics portfolio spanning reference labs, in-house diagnostics, imaging and software WARWICK, England, 7 Nov. 2023 /PRNewswire/ -- Antech, the full-service veterinary diagnostics business that is part of the Science & Diagno...

2023-11-07 15:30 1433

BioRay Announces First-Patient-In for Phase I Clinical Study of BRY812, a Novel LIV-1 Targeting Antibody Drug Conjugate

SHANGHAI, Nov. 7, 2023 /PRNewswire/ -- BioRay Pharmaceutical Co., Ltd. (hereinafter referred to as BioRay) announced that the first patient has been dosed in the Phase I Clinical trial of BRY812, a third-generation antibody-drug conjugate (ADC) targeting LIV-1 for the treatment of advanced malign...

2023-11-07 14:14 1139

87.5% ORR | Abbisko presented two clinical updates of Pimicotinib at the 2023 CTOS Annual Meeting

SHANGHAI, Nov. 6, 2023 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter) announced that two major clinical updates of its CSF-1R inhibitor pimicotinib(ABSK021)were presented at the 2023 Connective Tissue Oncology Society Annual Meeting, which is held inIreland from...

2023-11-07 12:31 1186

2023 World Laureates Association Prize winners awarded in Shanghai

SHANGHAI, Nov. 7, 2023 /PRNewswire/ -- The five winners of the 2023 World Laureates Association Prize (WLA Prize) received their awards for their ground-breaking achievements in computer science or mathematics and life science or medicine onNov. 6 at the opening ceremony of the 6th WLA Forum held...

2023-11-07 09:49 491

KN026 was Granted Breakthrough Therapy Designation by CDE

SUZHOU, China, Nov. 7, 2023 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. (stock code: 1093.HK) jointly announced, that the Center for Drug Evaluation (CDE) ofChina's National Medical Products Administration (NMPA) granted a Breakthrough Therapy d...

2023-11-07 08:51 1508

Unveiling the hidden struggles: Survey reveals worrying knowledge gap and emotional toll of infertility amidst record-low birth rates in Asia

* A survey conducted in seven Asian markets, including Singapore, revealed that respondents, on average, spent 6.8 years on their fertility journey, with 3.6 years dedicated to trying to conceive naturally.1,2 * In Indonesia, Japan, Korea, Singapore, and Vietnam, at least 70 percent of respon...

2023-11-07 08:15 1024

Unveiling the hidden struggles: Survey reveals worrying knowledge gap and emotional toll of infertility amidst record-low birth rates in Asia

* A survey conducted in seven Asian markets, including Taiwan, revealed that respondents, on average, spent 6.8 years on their fertility journey, with 3.6 years dedicated to trying to conceive naturally.1,2 * In Indonesia, Japan, Korea, Singapore, and Vietnam, at least 70 percent of responden...

2023-11-07 08:15 1066

Unveiling the hidden struggles: Survey reveals worrying knowledge gap and emotional toll of infertility amidst record-low birth rates in Asia

* A survey conducted in seven Asian markets, including Japan, revealed that respondents, on average, spent 6.8 years on their fertility journey, with 3.6 years dedicated to trying to conceive naturally.1,2 * In Indonesia, Japan, Korea, Singapore, and Vietnam, at least 70 percent of respondent...

2023-11-07 08:15 1073

Unveiling the hidden struggles: Survey reveals worrying knowledge gap and emotional toll of infertility amidst record-low birth rates in Asia

* A survey conducted in seven Asian markets, including Indonesia, revealed that respondents, on average, spent 6.8 years on their fertility journey, with 3.6 years dedicated to trying to conceive naturally.1,2 * In Indonesia, Japan, Korea, Singapore, and Vietnam, at least 70 percent of respon...

2023-11-07 08:15 1055

Unveiling the hidden struggles: Survey reveals worrying knowledge gap and emotional toll of infertility amidst record-low birth rates in Asia

* A survey conducted in seven Asian markets, including South Korea, revealed that respondents, on average, spent 6.8 years on their fertility journey, with 3.6 years dedicated to trying to conceive naturally.1,2 * In Indonesia, Japan, South Korea, Singapore, and Vietnam, at least 70 percent o...

2023-11-07 08:15 1104

Unveiling the hidden struggles: Survey reveals worrying knowledge gap and emotional toll of infertility amidst record-low birth rates in Asia

* A survey conducted in seven Asian markets, including India, revealed that respondents, on average, spent 6.8 years on their fertility journey, with 3.6 years dedicated to trying to conceive naturally.1,2 * In Indonesia, Japan, Korea, Singapore, and Vietnam, at least 70 percent of respondent...

2023-11-07 08:15 968

Unveiling the hidden struggles: Survey reveals worrying knowledge gap and emotional toll of infertility amidst record-low birth rates in Asia

* A survey conducted in seven Asian markets, including Vietnam, revealed that respondents, on average, spent 6.8 years on their fertility journey, with 3.6 years dedicated to trying to conceive naturally.1,2 * In Indonesia, Japan, Korea, Singapore, and Vietnam, at least 70 percent of responde...

2023-11-07 08:15 1068

Clover Completes BLA Submission for Seasonal Influenza Vaccine in Brazil

-- Clover's seasonal influenza vaccine BLA submission has been completed in Brazil, boosting Clover's global presence --  SHANGHAI, Nov. 7, 2023 /PRNewswire/ -- Clover Biopharmaceuticals, Ltd.  (Clover; HKEX: 02197), a global commercial-stage biotechnology compa...

2023-11-07 08:00 1349
1 ... 75767778798081 ... 808